Research information only, not medical advice. Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 24, 2026 (evaluated indication: Cerebral ischemia, migraine, trigeminal neuralgia). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
Semax at a glance
As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.
The peptides on the agenda are covered in the July 2026 FDA peptide meeting .
Evidence profile
52 studies- Human trial 3 · 6%
- Review 13 · 25%
- Animal 30 · 58%
- In-vitro 4 · 8%
- Unknown 2 · 4%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2026-04-22 US-FDA
Removed from the FDA 503A 'do not compound' Category 2 (nominations withdrawn) — still not eligible for compounding. source
- 2026-07-24 US-FDA · upcoming
FDA Pharmacy Compounding Advisory Committee vote (evaluated indication: Cerebral ischemia, migraine, trigeminal neuralgia); docket FDA-2025-N-6895. source
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2025Study of the effectiveness of the drug «Semax» in the complex treatment of non-proliferative diabetic retinopathy
This study evaluates the effectiveness of Semax combined with calcium dobesilate in preventing progression of non-proliferative diabetic retinopathy in 87 patients.
- Human trial 2026[Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]
This study evaluated the effect of combined physiotherapeutic treatment on functional retinal parameters in patients after surgery for rhegmatogenous retinal detachment with favorable anatomical outcomes, comparing it to nasal Semax drops.
- Human trial 2026Project Title:"A 3-Month Pilot Pre-Trial of a Multi-Peptide Protocol (BPC-157/KPV/GHK-Cu Blend + TB-500 + Ara290 + Semax) for Arthritis, Cartilage Repair, Neuropathic Pain, and Mobility in Older Adults
This pilot pre-trial investigated the effects of a multi-peptide protocol on arthritis, cartilage repair, neuropathic pain, and mobility in older adults.
- Review 2026Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
- Review 2026Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Review 2025Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases
- Review 2026Therapeutic Peptides: An Evidence-Tiered Survey Across Neuroplasticity, Anti-Ageing, Fitness, and Tissue Repair: A Critical Review
This critical review surveys 20 therapeutic peptides across four clinical domains using a four-tier evidence framework, highlighting that most compounds lack robust human evidence.
- Review 2026Therapeutic Peptides: An Evidence-Tiered Survey Across Neuroplasticity, Anti-Ageing, Fitness, and Tissue Repair: A Critical Review
This critical review surveys 20 therapeutic peptides across four clinical domains using a four-tier evidence framework, highlighting that most compounds lack robust human evidence.
- Review 2026Therapeutic Peptides: An Evidence-Tiered Survey Across Neuroplasticity, Anti-Ageing, Fitness, and Tissue Repair: A Critical Review
This critical review surveys nineteen therapeutic peptides across four clinical domains using a four-tier evidence framework, highlighting that most compounds lack robust human evidence.
- Review 2026Therapeutic Peptides: An Evidence-Tiered Survey Across Neuroplasticity, Anti-Ageing, Fitness, and Tissue Repair: A Critical Review
This critical review surveys 20 therapeutic peptides across four clinical domains using a four-tier evidence framework, highlighting that most compounds lack robust human evidence.
+ 42 more studies indexed for Semax.
Frequently asked questions
- Is Semax approved for human use?
- Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 24, 2026 (evaluated indication: Cerebral ischemia, migraine, trigeminal neuralgia). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
- What does the research on Semax show?
- As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.